FDA 2011 Draft Guidance on Financial Disclosure by Clinical Investigators
Abstract:
The FDA released draft guidance in May 2011 to assist clinical investigators, industry and FDA staff in interpreting and complying with regulations governing financial disclosures by clinical investigators, 21 CFR Part 54.
Click here to download the file
Trending Compliance Trainings
Sterile Filtration of Pharmaceutical Products - Validation and Regulatory Requirements
By - Roger Cowan
On Demand Access Anytime
By - Roger Cowan
On Demand Access Anytime
FFIEC BSA/AML Examination Manual: What Compliance Officers Really Need to Know?
By - Doug Keipper
On Demand Access Anytime
By - Doug Keipper
On Demand Access Anytime
Technical Writing for the Pharmaceutical, Medical Device and Biotech Industries
By - Joy McElroy
On Demand Access Anytime
By - Joy McElroy
On Demand Access Anytime
Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
By - Michael Ferrante
On Demand Access Anytime
You Recently Viewed
